Disease · EFO_0010445

cocaine use disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cocaine use disorder. Diseases, record EFO_0010445. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010445

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cocaine use disorder
Open Targets ID: EFO_0010445
Highest stage of its drugs: Phase 3, for 1 of its 46 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs46

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHADONE	CHEMBL651	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PROGESTERONE	CHEMBL103	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
LORCASERIN	CHEMBL360328	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
AMPHETAMINE	CHEMBL405	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CARIPRAZINE	CHEMBL2028019	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CLAVULANIC ACID	CHEMBL777	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXTROAMPHETAMINE	CHEMBL612	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GALANTAMINE	CHEMBL659	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MAVOGLURANT	CHEMBL3087515	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 46

See all 46 drugs

Targets128

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Sodium-dependent noradrenaline transporter	5	Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Phase 2	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A3	Sodium-dependent dopamine transporter	5	Dopamine transporter inhibitor; Dopamine transporter releasing agent	Phase 2	https://conductscience.org/library/genes/6531	Drugs and targets
DRD2	D(2) dopamine receptor	4	D2-like dopamine receptor agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D(3) dopamine receptor	4	D2-like dopamine receptor agonist; Dopamine D3 receptor agonist; Dopamine D3 receptor modulator	Phase 2	https://conductscience.org/library/genes/1814	Drugs and targets
OPRM1	Mu-type opioid receptor	4	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	3	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	3	Serotonin 2c (5-HT2c) receptor agonist; Serotonin 2c (5-HT2c) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3358	Drugs and targets
SCN10A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6323	Drugs and targets

1 to 10 of 128

See all 128 targets

Trials57

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03007394	Lorcaserin in the Treatment of Cocaine Use Disorder	Phase 2	272	2020-06-19	Cocaine-Related Disorders	LORCASERIN	Its record names the disease	ClinicalTrials.gov
NCT00350870	CBT With Disulfiram and Contingency Management	Phase 1	181	2014-12-03	Cocaine Abuse	DISULFIRAM	Its record names the disease	ClinicalTrials.gov
NCT01986075	A Sequenced Behavioral and Medication Intervention for Cocaine Dependence	Phase 1/2	145	2022-01-25	Cocaine Dependence	AMPHETAMINE	Its record names the disease	ClinicalTrials.gov
NCT02682784	Neural Substrates of Emotion: Impact of Cocaine Dependence	Phase 2	138	2021-10-21	Cocaine Use Disorder	OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT00809835	Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse	Phase 2	120	2017-06-12	Cocaine Dependence	GALANTAMINE	Its record names the disease	ClinicalTrials.gov
NCT01393457	Cognitive Remediation for Cocaine Dependence	Phase 2	119	2018-03-29	Cocaine Dependence	CARBIDOPA, LEVODOPA, ROPINIROLE	Its record names the disease	ClinicalTrials.gov
NCT02896712	Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention	Phase 2	118	2023-02-08	Cocaine-Related Disorders	MODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT01531153	Cognitive Enhancement as a Target for Cocaine Pharmacotherapy	Not applicable	93	2018-10-26	Addiction	GALANTAMINE	Its record names the disease	ClinicalTrials.gov
NCT03242928	Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)	Phase 2	68	2021-02-04	Cocaine-related Disorder	MAVOGLURANT	Its record names the disease	ClinicalTrials.gov
NCT03953612	The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders	Early phase 1	58	2024-07-03	Cocaine-Related Disorders	PREGNENOLONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 57

See all 57 trials

Comparisons in its trials23

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lorcaserin vs Placebo Oral Capsule: The Secondary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment Who Are Either Non-Drinkers or Who Are Attempting Alcohol Abstinence	0 of 118	3 of 124	242	NCT03007394	Trial comparisons
Lorcaserin vs Placebo Oral Capsule: The Primary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment in the Pre-qualified for Primary Efficacy Endpoint (PPEE) Population	1 of 118	4 of 124	242	NCT03007394	Trial comparisons
Lorcaserin vs Placebo Oral Capsule: deaths from any cause	0 of 118	0 of 124	242	NCT03007394	Trial comparisons
Lorcaserin vs Placebo Oral Capsule: serious adverse events	4 of 118	6 of 124	242	NCT03007394	Trial comparisons
Computer-assisted CBT Plus Mixed-Amphetamine Salts- Extended Release (MAS-ER) vs Computer-assisted CBT Plus Placebo: Those Achieving Three Consecutive Weeks of Cocaine Abstinence at the End of the Trial.	7 of 45	5 of 41	86	NCT01986075	Trial comparisons
AFQ056 vs Placebo: deaths from any cause	0 of 31	0 of 37	68	NCT03242928	Trial comparisons
AFQ056 vs Placebo: serious adverse events	0 of 31	1 of 37	68	NCT03242928	Trial comparisons
Progesterone vs Placebo: serious adverse events	0 of 25	0 of 25	50	NCT01249274	Trial comparisons
Varenicline vs Placebo: serious adverse events	0 of 13	0 of 16	29	NCT00567320	Trial comparisons
Experimental vs Control: deaths from any cause	0 of 16	0 of 6	22	NCT03192995	Trial comparisons

1 to 10 of 23

See all 23 comparisons in its trials

Papers from its trials32

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34265007	RESULT	1	PubMed
26543027	RESULT	1	PubMed
20716302	RESULT	1	PubMed
18068905	RESULT	1	PubMed
17931826	RESULT	1	PubMed
17907858	RESULT	1	PubMed
17624688	RESULT	1	PubMed
17523584	RESULT	1	PubMed
17084789	RESULT	1	PubMed
16887281	RESULT	1	PubMed

1 to 10 of 32

See all 32 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0010445

GET https://conductscience.org/api/diseases/v1/EFO_0010445/drugs?page=2

API reference For AI assistants